Oncimmune new ImmunoINSIGHTS contract further validates offering and supports expected sales growth

Oncimmune Holdings plc (LON:ONC) announced a new contract with the Dana-Farber Cancer Institute (Harvard Medical School affiliate based in Boston, US) whereby the latter will utilise Oncimmune’s proprietary SeroTagTM ‘biomarker discover engine’ to identify predictive patient responses to novel checkpoint inhibitor (CPI) based cancer therapies. As in the case of yesterday’s announcement (see our note Cutting edge COVID-19 research validates ImmunoINSIGHTS as a valuable research tool) this new deal further validates the commercial value of Oncimmune’s ImmunoINSIGHTS offering, although in this case the news is also indicative of additional revenue from a new deal. The news further supports our expectations of continuing revenue and earnings growth for the company.  Our valuation and current forecasts are currently under review pending an update by a new analyst. 

Dana-Farber is a world-leading centre of excellence in cancer research

The institute is an acclaimed global leader in pioneering cancer research, from preclinical investigations through to clinical trials. Employing nearly 5,000 staff it is ranked the number 3 cancer hospital in the world, oversees in  excess of 1,100 clinical trials and enjoys extensive support in terms of Federal funding.

Checkpoint inhibitors are at the cutting edge of cancer therapy

Therapies to be investigated include Merck’s Keytruda (pembrolizumab), Pfizer’s Opdivo (nivolumab), Roche/Genentech’s Tecentriq (atezolizumab) and Astrazeneca’s Imfinzi (durvalumab), which together generated combined 2021 sales of $26.6bn. The future commercial success of CPI sales will benefit greatly from better understanding of patient responses, and we hope that this work with Dana-Farber will facilitate further immune-oncology contracts with CPI companies, including those listed above. We note that Oncimmune already has a contract with an undisclosed US-based global pharmaceutical company working in this area.

Today’s news is evidence that new ImmunoINSIGHTS contracts are being won

Oncimmune’s March 2021 £9m (gross) fundraise facilitated the expansion of the ImmunoINSIGHTS franchise, and is supporting an increase in analytical capacity, from c10,000 to c40,000 samples by Q1 FY2023. Laboratory and commercial operations are being expanded in Dortmund and the US respectively. On a broader basis, the company also reported that going forward ImmunoINSIGHTS sales would benefit from new contracts with Roche, its subsidiary Genentech, Cedars-Sinai Medical Center and an undisclosed leading US-based global pharmaceutical company. Oncimmune expects that new ImmunoINSIGHTS contracts over FY2021 and Q1 FY2022 will likely constitute 50% of FY2022 revenue. Sales growth is evidenced by today’s news. With over 90% of ImmunoINSIGHTS revenue likely to be US-based, the company is considering building a duplicate US laboratory and hiring a US business development team to support its efforts in this geography.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    AssetCo plc

    AssetCo performs better than forecasts says Zeus

    AssetCo plc (LON:ASTO) has just completed its acquisition of River and Mercantile Group “RMG”, which has resulted in an increase in shares in issue from 8.4m to 14.4m. RMG has an “established and well-respected equities team

    Tatton Asset Management Plc

    Tatton Asset Management meeting or beating Zeus forecasts

    Tatton Asset Management plc (LON:TAM) results to March 2022 are in line with its April trading update, confirming profitable growth with high retention. Headlines are: ¨ Assets under management (“AUM”) rose 26.1% to £11.34bn (2021: £8.99bn)

    Castings plc

    Castings Plc outlook underpinned by new platforms says Zeus

    Castings plc (LON:CGS) FY22 results show a marked recovery on the pandemic impacted FY21 numbers with volumes broadly in line with pre-Covid levels, albeit c.5% below FY19 peak. Revenue increased 29.5% to £148.6m (FY21: £114.7m) with

    OnTheMarket Plc

    OnTheMarket “delivering on expectations” says Zeus

    OnTheMarket plc (LON:OTMP) full year results to January 2022 are in line with the February trading update: ¨ 32% rise in revenue to £30.4m (FY21: £23.0m); ¨ 12% rise in Group adjusted operating profit to £2.7m

    DWF Group Plc

    DWF Group is significantly undervalued says Zeus

    DWF Group plc (LON:DWF) has announced it is on track to deliver our FY22 adjusted PBT forecast despite some challenges particularly on utilisation during H2. Lock up days also continue to fall, and we sense increasing

    Redde Northgate buy back own shares

    Redde Northgate plc (LON:REDD) have today announced that on the 5th May 2022 it purchased the following number of its own shares to be held in treasury: Class of shares :  Ordinary shares of 50p (“shares”) Number

    boohoo Plc

    boohoo group total group sales +61% since FY2020

    boohoo group plc (LON:BOO) have today published final results for the year ended 28th February 2022. Investing for the future ·    Significantly increased market share in the UK and US since FY2020. Total group sales +61% since FY2020 ·    Extended